The following SAHPRA Guidelines have been published on the SAHPRA website:

  1. Guideline 7.02: Complementary Medicines - Roadmap and Transitional Arrangements (March 2021 - version 2.2) [for implementation]
  2. Guideline 7.04: Complementary Medicines - Health Supplements, Annexures M and N (March 2021 - version 4.1) [published for public comment by 30 June 2021]
  3. Guideline 7.06: Complementary Medicines - Guidelines on Specified Substances; Annexure 4: Cannabidiol (CBD) (March 2021 - version 3.1) [published for public comment by 30 June 2021]
  4. Notice to Stakeholders: Guidelines on Specified Substances; Annexure 4: Cannabidiol (CBD) (23 March 2021)
  5. Comment Template: SAHPRA CM Guidelines

All comment related to items 2 and 3 may be submitted online by the prescribed deadline. The comment submission area and all documents may be downloaded from Category D Medicines - Guidelines - Documents for Download.